Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004802 | 1.00 | ATM (0.44) | ATML3MBTL1TDP1HPGDALOX15 | |
| SCHEMBL15508892 | 0.88 | GAA (0.51) | TDP1ALOX15HSD17B10ELANEMAPT | |
| SCHEMBL15515753 | 0.88 | GAA (0.51) | TDP1ALOX15HSD17B10ELANEMAPT | |
| SCHEMBL1006524 | 0.83 | AKR1C3 (0.48) | ATML3MBTL1TDP1HPGDALOX15 | |
| SCHEMBL6463471 | 0.82 | ATM (0.40) | ATML3MBTL1TDP1HPGDALOX15 | |
| SCHEMBL11547869 | 0.81 | LMNA (0.49) | L3MBTL1TDP1HPGDHSD17B10ALDH1A1 | |
| SCHEMBL11570625 | 0.81 | LMNA (0.49) | L3MBTL1TDP1HPGDHSD17B10ALDH1A1 | |
| SCHEMBL8228620 | 0.81 | TDP1 (0.42) | ATML3MBTL1TDP1HPGDALOX15 | |
| SCHEMBL10792060 | 0.81 | TDP1 (0.42) | ATML3MBTL1TDP1HPGDALOX15 | |
| SCHEMBL9685241 | 0.81 | TDP1 (0.42) | ATML3MBTL1TDP1HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275398-B1 | APPLICATION OF AN IRIDIUM COMPLEX IN ASYMMETRIC CATALYTIC HYDROGENATION OF AN UNSATURATED CARBOXYLIC ACID | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2016-05-04 | — | — | EP | claimed |
| US-20110092732-A1 | APPLICATION OF IRIDIUM COMPLEXES IN ASYMMETRIC CATALYTIC HYDROGENATION OF UNSATURATED CARBOXYLIC ACIDS | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2011-04-21 | — | — | US | claimed |
| EP-2275398-A1 | APPLICATION OF THE IRIDIUM COMPLEX IN ASYMMETRIC CATALYTIC HYDROGENATION FOR UNSATURATED CARBOXYLIC ACID | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2011-01-19 | — | — | EP | claimed |
| US-11931365-B2 | Use of PPAR-delta agonists in the treatment of disease | RENEO PHARMACEUTICALS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240016809-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | RENEO PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023147309-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | RENEO PHARMACEUTICALS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230233570-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | RENEO PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11566140-B2 | Exterior coating composition | TROY CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | WASHINGTON UNIVERSITY | 2022-11-24 | — | — | US | disclosed |
| EP-4031124-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | Reneo Pharmaceuticals, Inc. (US) | 2022-07-27 | — | — | EP | disclosed |
| CN-114727976-A | Use of PPAR-delta agonists in the treatment of renal disease | 雷内奥制药公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20110092732-A1 | APPLICATION OF IRIDIUM COMPLEXES IN ASYMMETRIC CATALYTIC HYDROGENATION OF UNSATURATED CARBOXYLIC ACIDS | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2011-04-21 | — | — | US | disclosed |
| US-20110092732-A1 | APPLICATION OF IRIDIUM COMPLEXES IN ASYMMETRIC CATALYTIC HYDROGENATION OF UNSATURATED CARBOXYLIC ACIDS | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2011-04-21 | — | — | US | disclosed |
| US-20110092732-A1 | APPLICATION OF IRIDIUM COMPLEXES IN ASYMMETRIC CATALYTIC HYDROGENATION OF UNSATURATED CARBOXYLIC ACIDS | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2011-04-21 | — | — | US | disclosed |
| EP-2275398-A1 | APPLICATION OF THE IRIDIUM COMPLEX IN ASYMMETRIC CATALYTIC HYDROGENATION FOR UNSATURATED CARBOXYLIC ACID | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2011-01-19 | — | — | EP | disclosed |
| EP-2275398-A1 | APPLICATION OF THE IRIDIUM COMPLEX IN ASYMMETRIC CATALYTIC HYDROGENATION FOR UNSATURATED CARBOXYLIC ACID | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2011-01-19 | — | — | EP | disclosed |
| EP-2105432-A1 | Process for Producing Chromone Compound | Sumitomo Chemical Company, Limited (JP) | 2009-09-30 | — | — | EP | disclosed |
| US-6846777-B2 | Synergistic biocidal composition | THOR GMBH (DE) | 2005-01-25 | — | — | US | disclosed |
| US-20030199490-A1 | Synergistic biocidal composition | THOR GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
| US-4661617-A | PESTICIDES | SANDOZ LTD. (CH) | 1987-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | PPARG, PPARA, PPARD | ATM 1188/4885L3MBTL1 3816/4885TDP1 4243/4885 |
| US-11931365-B2 | Use of PPAR-delta agonists in the treatment of disease | PPARG, PPARD, PPARA | ATM 4161/4885L3MBTL1 4028/4885TDP1 3595/4885 |
| US-20110092732-A1 | APPLICATION OF IRIDIUM COMPLEXES IN ASYMMETRIC CATALYTIC HYDROGENATION OF UNSATURATED CARBOXYLIC ACIDS | HDHD5, ELOVL5, FASN | ATM 4182/4885L3MBTL1 4329/4885TDP1 4705/4885 |
| US-20230233570-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | PPARG, PPARD, PPARA | ATM 4161/4885L3MBTL1 4028/4885TDP1 3595/4885 |
| US-20240016809-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | PPARG, PPARD, PPARA | ATM 4161/4885L3MBTL1 4028/4885TDP1 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.